Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2015

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	For the Three Months Ended December 31,				For the Six Months Ended December 31,
Medical Indication	2015		2014		2015		2014
Antibiotic	$	2,828	$	3,346	$	5,556	$	6,349
Cardiovascular	13,082		18,333		21,385		37,272
Central Nervous System	6,077		—		6,077		—
Gallstone	18,719		16,719		38,691		28,480
Gastrointestinal	8,617		—		8,693		—
Glaucoma	6,543		5,516		13,365		10,207
Gout	83		2,990		148		5,289
Migraine	5,705		6,938		11,247		12,733
Muscle Relaxant	1,393		2,300		3,054		2,640
Obesity	851		953		1,830		1,868
Pain Management	8,074		7,567		16,207		14,222
Respiratory	1,396		—		1,396		—
Thyroid Deficiency	37,432		44,535		78,534		77,881
Urinary	3,378		—		3,593		—
Other	10,610		5,625		21,445		11,268
Contract manufacturing revenue	2,271		—		2,271		—
Total	$	127,059	$	114,822	$	233,492	$	208,209

Summary of products which accounted for at least 10% of net sales

	For the Three Months Ended December 31,				For the Six Months Ended December 31,
	2015		2014		2015		2014
Product 1	29	%	39	%	34	%	37	%
Product 2	15	%	15	%	17	%	14	%
Product 3	5	%	15	%	6	%	16	%

Summary of customers which accounted for at least 10% of net sales

	For the Three Months Ended December 31,				For the Six Months Ended December 31,
	2015		2014		2015		2014
Customer A	27	%	31	%	14	%	31	%
Customer B	18	%	8	%	9	%	8	%